8-K: Coherus Oncology Q1 2026 Results: LOQTORZI Revenue Grows, Pipeline Advances

Coherus Oncology reported Q1 2026 financial results, with LOQTORZI net revenue reaching $11.8 million, alongside updates on clinical trial progress for tagmokitug and casdozokitug.

Summary

• Coherus Oncology reported first quarter 2026 financial results, with net revenue from continuing operations at $12.3 million.
• LOQTORZI net product revenue increased by 61% year-over-year to $11.8 million in Q1 2026, despite a 5% sequential decrease from Q4 2025 attributed to weather and seasonality.
• The company ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
• Clinical trials for pipeline candidates tagmokitug and casdozokitug are progressing, with data readouts anticipated throughout 2026.
• A public offering in Q1 2026 raised $53.6 million in net proceeds.
• Net loss from continuing operations was $36.9 million, or $(0.27) per share, an improvement from a net loss of $47.4 million, or $(0.41) per share, in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong year-over-year revenue growth for LOQTORZI and progress in pipeline development, balanced by a sequential revenue dip and continued net losses.

Positives

• LOQTORZI net revenue increased 61% to $11.8 million in Q1 2026 compared to Q1 2025.
• Q1 2026 saw the highest volume of new patient starts for LOQTORZI to date.
• Average duration of treatment for existing LOQTORZI patients continued to grow.
• The company ended Q1 2026 with $167.0 million in cash, cash equivalents, and marketable securities.
• Net loss from continuing operations improved to $(0.27) per share in Q1 2026 from $(0.41) per share in Q1 2025.
• Non-GAAP net loss from continuing operations improved to $(0.25) per share in Q1 2026 from $(0.35) per share in Q1 2025.
• Patient accrual is complete for the 1L HCC Phase 2 randomized clinical trial for casdozokitug, with data readouts on track.
• Tagmokitug development is advancing with promising pharmacological and clinical program differentiation.

Negatives

• LOQTORZI net revenue decreased by 5% sequentially from $12.4 million in Q4 2025 to $11.8 million in Q1 2026.
• The company reported a net loss from continuing operations of $36.9 million in Q1 2026.
• Cash, cash equivalents, and marketable securities decreased from $172.1 million at the end of 2025 to $167.0 million at the end of Q1 2026.

Risks

• Risks and uncertainties inherent in the clinical drug development process.
• Dependence on the ability to raise funds in the future, which may not be available on acceptable terms.
• Risks related to existing and potential collaboration partners.
• Risks associated with Coherus' competitive position with LOQTORZI and its product candidates.
• Risks associated with the ability to successfully commercialize and maintain and increase revenues for LOQTORZI.
• Risks and uncertainties of the regulatory approval process, including the speed of regulatory review and timing of filings.
• Risk of FDA review issues.
• Risks and uncertainties of possible litigation.

Future Outlook

The company anticipates multiple data readouts from its pipeline programs as planned in 2026, including initial data from the casdozokitug/toripalimab/bevacizumab Phase 2 trial in mid-2026, and initial data readouts for tagmokitug combination studies in mid-2026 and 2H 2026. A Phase 1b clinical study in mCRPC with pasritamig is anticipated to begin in the fall of 2026.

Management Comments

• "We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination with our pipeline products."
• "We also continue to explore opportunities across cancers and non-proprietary novel combinations with tagmokitug, our potentially best-in-class CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data."
• "Casdozokitug is the only known clinical stage IL-27 antagonist, and the first line HCC study in combination with LOQTORZI is now fully enrolled. We are tracking to initial data around mid-year."
• "The tagmokitug program is also on track, with continued enrollment across all cohorts. We also continue to progress the first-in-class pasritamig combination study in metastatic castration-resistant prostate cancer (mCRPC), which we anticipate initiating in the fall. We are on target for multiple data readouts as planned in 2026."

Industry Context

StockSavvy.ai notes that Coherus Oncology's Q1 2026 results reflect the ongoing challenges and opportunities in the competitive oncology market. The growth in LOQTORZI revenue is a positive sign, but the sequential dip highlights market dynamics. The company's focus on advancing its pipeline candidates, tagmokitug and casdozokitug, aligns with industry trends towards combination therapies and targeted immunotherapies.

Comparison to Industry Standards

• LOQTORZI's Q1 2026 revenue of $11.8 million represents a 61% year-over-year increase, indicating strong market penetration in its approved indication for nasopharyngeal carcinoma, an area with an estimated $250 million addressable market.
• The net loss from continuing operations of $(0.27) per share is an improvement from $(0.41) per share in the prior year, reflecting efforts to manage expenses, though still indicating an investment phase typical for many biotech companies developing novel therapies.
• The company's cash position of $167.0 million provides runway, but the continued net burn rate necessitates careful financial management and potential future financing, a common scenario for companies in clinical development and early commercialization phases.

Stakeholder Impact

• Shareholders: Positive impact from LOQTORZI revenue growth and pipeline advancements, offset by continued net losses and a slight decrease in cash reserves. The capital raise provides funding but dilutes existing shareholders.
• Employees: Potential impact from R&D expense decreases due to headcount reduction, but continued investment in pipeline suggests ongoing employment opportunities.
• Customers (Patients/Physicians): Continued availability and education on LOQTORZI for nasopharyngeal carcinoma. Progress in pipeline trials offers hope for future treatment options.
• Suppliers/Creditors: Continued operations and revenue generation support ongoing business relationships. The company's cash position is a key factor for creditors.

Next Steps

• Continue to educate physicians on LOQTORZI's positioning as the only approved and available therapy for R/M nasopharyngeal carcinoma and its NCCN recommended status.
• Communicate six-year overall survival follow-up results from the Phase 3 JUPITER-02 trial.
• Continue enrollment across all cohorts for tagmokitug studies.
• Initiate the first-in-class pasritamig combination study in metastatic castration-resistant prostate cancer (mCRPC) in the fall of 2026.
• Anticipate initial data readouts for casdozokitug Phase 2 trial in mid-2026.
• Anticipate initial data readouts for tagmokitug combination studies in mid-2026 and 2H 2026.

Key Dates

Recommendation

The company shows positive year-over-year growth for its key product, LOQTORZI, and is making progress on its pipeline. However, the sequential revenue dip, ongoing net losses, and the need for future capital raises suggest a 'hold' recommendation. Investors should monitor pipeline data readouts and commercial execution closely.

Keywords

Coherus Oncology, LOQTORZI, toripalimab-tpzi, oncology, nasopharyngeal carcinoma, clinical trials, tagmokitug, casdozokitug